Flag of the European Union EU Clinical Trials Register Help

Clinical trials for placebo

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44341   clinical trials with a EudraCT protocol, of which   7370   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    12,689 result(s) found for: placebo. Displaying page 240 of 635.
    «« First « Previous 236  237  238  239  240  241  242  243  244  Next» Last»»
    EudraCT Number: 2012-002806-31 Sponsor Protocol Number: 20120230(KAI-4169-007) Start Date*: 2013-02-12
    Sponsor Name:KAI Pharmaceuticals, Inc. (a subsidiary of Amgen, Inc.)
    Full Title: A Randomized, Double-blind, Placebo-controlled, Phase 3 Study to Assess the Efficacy and Safety of AMG 416 in the Treatment of Secondary Hyperparathyroidism in Subjects With Chronic Kidney Disease ...
    Medical condition: Secondary hyperparathyroidism in subjects with chronic kidney disease
    Disease: Version SOC Term Classification Code Term Level
    14.1 10014698 - Endocrine disorders 10020708 Hyperparathyroidism secondary PT
    14.1 10014698 - Endocrine disorders 10020706 Hyperparathyroidism NOS LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) CZ (Completed) IT (Completed) ES (Completed) SE (Completed) HU (Completed) PL (Completed) NL (Completed) DE (Completed)
    Trial results: View results
    EudraCT Number: 2011-001230-42 Sponsor Protocol Number: CTKI258A2210 Start Date*: 2012-03-15
    Sponsor Name:Novartis Pharma Services AG
    Full Title: A multicenter, randomized, double blind, placebo controlled, phase II trial evaluating the safety and efficacy of TKI258 combined with fulvestrant, in postmenopausal patients with HER2- and HR+ bre...
    Medical condition: Breast cancer, HER2 negative and HR positive, with evidence of disease progression after prior endocrine therapy
    Disease:
    Population Age: Adults Gender: Female
    Trial protocol: AT (Completed) ES (Completed) HU (Completed) BE (Completed) IT (Completed) NL (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2008-001087-36 Sponsor Protocol Number: Bay43-9006/12414 Start Date*: 2008-08-18
    Sponsor Name:Bayer Healthcare AG
    Full Title: A Phase III randomized, double-blind, placebo-controlled study of sorafenib as adjuvant treatment for hepatocellular carcinoma after surgical resection or local ablation.
    Medical condition: To evaluate the clinical benefit of sorafenib vs placebo as adjuvant treatment in subjects with HCC who received potentially curative treatment (surgical resection or local ablation).
    Disease: Version SOC Term Classification Code Term Level
    14.1 100000004864 10019830 Hepatocellular carcinoma resectable LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Completed) GB (Completed) ES (Completed) AT (Completed) BE (Completed) FR (Completed) IT (Completed) PT (Completed) DE (Completed) GR (Completed) BG (Completed)
    Trial results: View results
    EudraCT Number: 2016-003452-75 Sponsor Protocol Number: PTG-100-02 Start Date*: 2017-02-20
    Sponsor Name:Protagonist Therapeutics, Inc
    Full Title: A PHASE 2B RANDOMISED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL ADAPTIVE 2-STAGE, MULTI-CENTRE STUDY TO EVALUATE THE SAFETY AND EFFICACY OF ORAL PTG-100 INDUCTION IN SUBJECTS WITH MODERATE TO SEV...
    Medical condition: Moderate to Severe Active Ulcerative Colitis
    Disease: Version SOC Term Classification Code Term Level
    20.1 100000004856 10045365 Ulcerative colitis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: LV (Prematurely Ended) HU (Prematurely Ended) BE (Completed) CZ (Prematurely Ended) NL (Prematurely Ended) PL (Prematurely Ended) HR (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2007-001283-73 Sponsor Protocol Number: 109493 Start Date*: 2007-08-16
    Sponsor Name:GlaxoSmithKline Biologicals
    Full Title: A double-blind, randomized, placebo-controlled Phase III study to assess the efficacy of recMAGE-A3 + AS15 Antigen-Specific Cancer Immunotherapeutic as adjuvant therapy in patients with resectable ...
    Medical condition: Adjuvant therapy in patients with MAGE-A3-positive Non-Small Cell Lung Cancer (NSCLC) and who have had complete surgical resection
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10029520 Non-small cell lung cancer stage IIIA PT
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10061873 Non-small cell lung cancer PT
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10029517 Non-small cell lung cancer stage I PT
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10029518 Non-small cell lung cancer stage II PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Prematurely Ended) DE (Prematurely Ended) IE (Prematurely Ended) FI (Prematurely Ended) ES (Prematurely Ended) SI (Prematurely Ended) FR (Completed) SE (Prematurely Ended) GR (Prematurely Ended) IT (Prematurely Ended) LV (Prematurely Ended) AT (Completed) NL (Prematurely Ended) HU (Prematurely Ended) CZ (Prematurely Ended) EE (Prematurely Ended) GB (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2008-005889-32 Sponsor Protocol Number: A0081186 Start Date*: 2009-07-17
    Sponsor Name:Pfizer Inc. 235 East 42nd Street, New York, NY 10017
    Full Title: RANDOMIZED, DOUBLE-BLIND, 12-MONTH STUDY OF PREGABALIN IN SUBJECTS WITH RESTLESS LEGS SYNDROME
    Medical condition: Restless Legs Syndrome
    Disease: Version SOC Term Classification Code Term Level
    9.1 10058920 Restless legs syndrome LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Completed) DE (Completed) ES (Completed) FI (Completed) NL (Completed) AT (Completed) GB (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2013-003953-13 Sponsor Protocol Number: PPHM1202 Start Date*: 2014-04-01
    Sponsor Name:Peregrine Pharmaceuticals, Inc.
    Full Title: A Phase III, Randomized, Double-Blind, Placebo-Controlled Multicenter Trial of Bavituximab Plus Docetaxel versus Docetaxel Alone in Patients with Previously Treated Stage IIIb/IV Non-Squamous Non...
    Medical condition: Stage IIIb/IV Non-Squamous Non Small-Cell Lung Cancer
    Disease: Version SOC Term Classification Code Term Level
    18.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10029522 Non-small cell lung cancer stage IV PT
    18.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10029521 Non-small cell lung cancer stage IIIB PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended) IT (Prematurely Ended) BE (Prematurely Ended) HU (Prematurely Ended) ES (Completed) GR (Prematurely Ended) RO (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2004-001959-11 Sponsor Protocol Number: CL3-16257-056 Start Date*: 2005-04-20
    Sponsor Name:Institut de Recherches Internationales
    Full Title: Effects of ivabradine on cardiovascular events in patients with stable coronary artery disease and left ventricular systolic dysfunction. A three-year randomised double-blind placebo-controlled int...
    Medical condition: Coronary artery disease
    Disease: Version SOC Term Classification Code Term Level
    7.0 10011078 PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed) LT (Completed) FI (Completed) LV (Completed) IT (Completed) CZ (Completed) SK (Completed) GB (Completed) DK (Completed) AT (Completed) SE (Completed) EE (Completed) DE (Completed) IE (Completed) ES (Completed)
    Trial results: View results
    EudraCT Number: 2006-000708-18 Sponsor Protocol Number: CL3-16257-063 Start Date*: 2006-08-23
    Sponsor Name:Institut de Recherches Internationales Servier
    Full Title: Effects of ivabradine on cardiovascular events in patients with moderate to severe chronic heart failure and left ventricular systolic dysfunction. A three-year randomised double-blind placebo-cont...
    Medical condition: cardiac failure chronic
    Disease: Version SOC Term Classification Code Term Level
    9.0 10007558 PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Completed) HU (Completed) BE (Completed) DE (Completed) NL (Completed) LT (Completed) DK (Completed) LV (Completed) FI (Completed) SI (Completed) CZ (Completed) EE (Completed) SK (Completed) IE (Completed) GB (Completed) BG (Completed) IT (Completed) PT (Completed) GR (Completed) AT (Completed) ES (Completed)
    Trial results: View results
    EudraCT Number: 2018-000226-58 Sponsor Protocol Number: A3921120 Start Date*: 2018-07-12
    Sponsor Name:Pfizer Inc., 235 East 42nd Street, New York, NY 10017
    Full Title: A Phase 3, Randomized, Double Blind, Placebo Controlled, Study Of The Efficacy And Safety Of Tofacitinib In Subjects With Active Ankylosing Spondylitis (AS)
    Medical condition: Ankylosing spondylitis (AS)
    Disease: Version SOC Term Classification Code Term Level
    20.0 10028395 - Musculoskeletal and connective tissue disorders 10002556 Ankylosing spondylitis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed) HU (Completed) CZ (Completed) ES (Completed) AT (Prematurely Ended) GB (Completed) DE (Prematurely Ended) BG (Completed)
    Trial results: View results
    EudraCT Number: 2010-021394-37 Sponsor Protocol Number: SP0976 Start Date*: 2011-03-08
    Sponsor Name:UCB Pharma SA
    Full Title: MULTICENTER, DOUBLE-BLIND, PLACEBO CONTROLLED, PARALLEL-GROUP, PHASE IV STUDY TO ASSESS THE EFFECT OF ROTIGOTINE ON NON-MOTOR SYMPTOMS IN PATIENTS WITH IDIOPATHIC PARKINSON’S DISEASE
    Medical condition: Parkinson's disease
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029205 - Nervous system disorders 10061536 Parkinson's disease PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) HU (Completed) BE (Completed) CZ (Completed) SK (Completed) ES (Completed) AT (Completed) BG (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2009-016366-88 Sponsor Protocol Number: 28431754DIA3002 Start Date*: 2010-05-17
    Sponsor Name:Janssen-Cilag International NV
    Full Title: A Randomized, Double-Blind, Placebo-Controlled, 3-Arm, Parallel-Group, Multicenter Study, to Evaluate the Efficacy, Safety, and Tolerability of Canagliflozin in the Treatment of Subjects With Type ...
    Medical condition: type 2 diabetes mellitus (T2DM) with inadequate glycemic control on combination therapy with metformin and a sulphonylurea (SU)
    Disease: Version SOC Term Classification Code Term Level
    12.1 10067585 Type 2 diabetes mellitus LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) DE (Prematurely Ended) GB (Completed) FR (Completed) ES (Completed) HU (Completed)
    Trial results: View results
    EudraCT Number: 2009-014940-12 Sponsor Protocol Number: CL2-44121-006 Start Date*: 2010-03-11
    Sponsor Name:Institut de Recherches Internationales Servier
    Full Title: Evaluation of the anti-arrhythmic effects of 3 oral dosages of S 44121 versus placebo in patients with chronic heart failure and left ventricular systolic dysfunction at risk for ventricular arrhyt...
    Medical condition: Chronic Heart Failure and left ventricular systolic dysfunction at risk for ventricular arrhythmia
    Disease: Version SOC Term Classification Code Term Level
    12.1 10007558 Cardiac failure chronic LLT
    12.1 10049694 Left ventricular dysfunction LLT
    12.1 10047281 Ventricular arrhythmia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed) HU (Completed) SK (Completed) ES (Completed) PT (Completed) GB (Completed) CZ (Completed) DE (Completed) BE (Completed)
    Trial results: View results
    EudraCT Number: 2012-003292-19 Sponsor Protocol Number: EFC12703 Start Date*: 2013-06-04
    Sponsor Name:Sanofi-Aventis Recherche & Développement
    Full Title: A randomized, double-blind, placebo-controlled, 2-arm parallel-group, multicenter, 24 week study assessing the safety and efficacy of lixisenatide in older patients with type 2 diabetes inadequatel...
    Medical condition: Type 2 Diabetes mellitus
    Disease: Version SOC Term Classification Code Term Level
    14.1 10027433 - Metabolism and nutrition disorders 10067585 Type 2 diabetes mellitus PT
    Population Age: Elderly Gender: Male, Female
    Trial protocol: GB (Completed) SE (Completed) ES (Completed) NO (Completed) DE (Completed) DK (Completed) BG (Completed)
    Trial results: View results
    EudraCT Number: 2010-019318-26 Sponsor Protocol Number: IMCL_CP12-0919_(I4T-IE-JVBF) Start Date*: 2010-09-27
    Sponsor Name:ImClone LLC
    Full Title: A Multicenter, Randomized, Double-Blind, Phase 3 Study of Ramucirumab (IMC-1121B) Drug Product and Best Supportive Care (BSC) Versus Placebo and BSC as Second-Line Treatment in Patients With Hepato...
    Medical condition: Hepatocellular Carcinoma
    Disease: Version SOC Term Classification Code Term Level
    14.1 100000004864 10019828 Hepatocellular carcinoma non-resectable LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FI (Completed) DE (Completed) CZ (Completed) PT (Completed) BE (Completed) ES (Completed) AT (Completed) FR (Completed) BG (Completed) HU (Completed) IT (Completed) SE (Completed) NO (Completed)
    Trial results: View results
    EudraCT Number: 2010-021297-11 Sponsor Protocol Number: I4T-MC-JVBA Start Date*: 2011-03-07
    Sponsor Name:Eli Lilly and Company Limited, Indianapolis
    Full Title: A Randomized, Double-Blind, Phase 3 Study of Docetaxel and Ramucirumab versus Docetaxel and Placebo in the Treatment of Stage IV Non-Small Cell Lung Cancer Following Disease Progression after One P...
    Medical condition: Stage IV Non-Small Cell Lung Cancer
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10029522 Non-small cell lung cancer stage IV PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) NL (Completed) ES (Completed) IT (Completed) NO (Completed) AT (Completed) SE (Completed) GR (Completed) GB (Completed) HU (Completed)
    Trial results: View results
    EudraCT Number: 2007-002066-35 Sponsor Protocol Number: A3921035 Start Date*: 2008-03-28
    Sponsor Name:Pfizer Inc, 235 East 42nd Street, New York, NY 10017
    Full Title: A PHASE 2B, RANDOMIZED, DOUBLE-BLIND, PLACEBO CONTROLLED ACTIVE COMPARATOR, MULTICENTER STUDY TO COMPARE 5 DOSE REGIMENS OF CP-690,550 AND ADALIMUMAB VERSUS PLACEBO, ADMINISTERED FOR 6 MONTHS IN TH...
    Medical condition: Rheumatoid Arthritis
    Disease: Version SOC Term Classification Code Term Level
    9.1 10039073 Rheumatoid arthritis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed) IT (Completed) GR (Completed) CZ (Completed) BG (Completed) SK (Completed) DE (Completed)
    Trial results: View results
    EudraCT Number: 2016-000657-12 Sponsor Protocol Number: ACT14820 Start Date*: 2016-11-09
    Sponsor Name:Genzyme Corporation
    Full Title: Multicenter, Randomized, Double-blind, Placebo Controlled Study to Assess the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of GZ/SAR402671 in Patients with Early-stage Parkinson's Disea...
    Medical condition: Parkinson's disease (PD) carrying a GBA mutation
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029205 - Nervous system disorders 10061536 Parkinson's disease PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Prematurely Ended) DE (Completed) AT (Prematurely Ended) ES (Prematurely Ended) PT (Prematurely Ended) IT (Prematurely Ended) GR (Completed)
    Trial results: View results
    EudraCT Number: 2019-002205-22 Sponsor Protocol Number: IM014029 Start Date*: 2020-05-01
    Sponsor Name:Bristol-Myers Squibb International Corporation
    Full Title: "A Randomized, Placebo-Controlled, Double-Blind, Multicenter Study to Assess the Efficacy and Safety of Branebrutinib Treatment in Subjects with Active Systemic Lupus Erythematosus or Primary Sjögr...
    Medical condition: SLE Sub-protocol: Systemic Lupus Erythematosus pSS Sub-protocol: Primary Sjögren’s Syndrome RA Sub-protocol: Rheumatoid Arthritis
    Disease: Version SOC Term Classification Code Term Level
    21.1 10028395 - Musculoskeletal and connective tissue disorders 10042945 Systemic lupus erythematosus PT
    21.0 10028395 - Musculoskeletal and connective tissue disorders 10040767 Sjogren's syndrome PT
    21.0 10028395 - Musculoskeletal and connective tissue disorders 10039073 Rheumatoid arthritis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) FR (Completed) BE (Completed) ES (Completed) PL (Completed) NL (Completed) DE (Completed)
    Trial results: View results
    EudraCT Number: 2016-002299-28 Sponsor Protocol Number: 20110203 Start Date*: 2017-01-17
    Sponsor Name:Amgen Inc
    Full Title: A Double-blind, Randomized, Placebo-controlled, Multicenter Study to Assess the Efficacy and Safety of Omecamtiv Mecarbil on Mortality and Morbidity in Subjects With Chronic Heart Failure With Redu...
    Medical condition: Chronic Heart Failure With Reduced Ejection Fraction
    Disease: Version SOC Term Classification Code Term Level
    19.0 100000004849 10008908 Chronic heart failure LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed) DE (Completed) BE (Completed) SE (Completed) CZ (Completed) ES (Completed) HU (Completed) NL (Completed) GB (Completed) PT (Completed) PL (Completed) AT (Completed) SK (Completed) BG (Completed) LT (Completed) GR (Completed) IT (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    «« First « Previous 236  237  238  239  240  241  242  243  244  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Wed Jun 04 14:34:52 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA